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C ompelling evidence has accumulated during recent years to support a theory that epidermal keratino-cytes synthesize and deliver to the extracellular space a wide variety of gene products. Each of these cellular products has unique physical-chemical properties re-
sulting from its biochemical structure that define its a) relative solu-
bility and ability to diffuse under physiologic conditions; b) proba-
bility of spontaneous assembly into higher order structures; c) 
specific affinity for ligands or cell surface receptors of target cells; 
and/or d) specific catalytic activity. Depending on the concentra-
tion of the gene product relative to its receptor or substrate, it may 
regulate stimulation or inhibition of cellular function. Gene prod-
ucts of keratinocytes known to be delivered to the extracellular 
space include cytokines, enzymes, and adhesion molecules, which 
together constitute the majority of the regulatory environment of 
epidermal tissue. Uninjured skin maintains a steady-state equilib-
rium of relatively slow metabolism of gene products. By compari-
son, injury or disease initiates expression by keratinocytes of several 
potent inflammatory mediators including interleukins (ILs)-l, -3, 
-6, -7, -8, -10, granulocyte colony stimulating factor (G-CSF) , 
granulocyte-monocyte stimulating factor (GM-CSF), and arachi-
donic acid metabolites that are associated with acute phase dermati-
tis and systemic response [1,2] . After whole body irradiation with 
ultraviolet (UV) light, significantly elevated circulating levels of 
ILs-1 and -6 correlate with induction of fever in humans [3,4]. 
Keratinocytes in culture also produce and release parathyroid hor-
1110ne-related protein (PTHrP), which is believed to participate in 
regulation of epidermal differentiation [5]. Collagenases and tissue 
plasminogen activator (TPA) are synthesized and secreted by cul-
tured keratinocytes [6,7], and transforming growth factor beta 1 
(TGF-fi1) has been shown to stimulate collagenase expression in 
keratinocytes [8]. Increased expression of intercellular adhesion 
molecule-l (ICAM-1) by keratinocytes after injury has been sug-
gested to facilitate T -lymphocyte infiltration in contact dermatitis, 
perhaps by establishment of a gradient toward the site of injury [9]. 
Several basement membrane components are secreted by keratino-
cytes, including the hemidesmosome protein, kalinin [10). Taich-
man and colleagues have demonstrated circu lating levels of human 
apolipoprotein E (Apo E) derived from epidermal keratinocytes in 
vitro l11, 12], and in serum after grafting of cultured epidermal kera-
tinocyte~ to .athymic mice [13]. From these kinds of examples, it 
fo llows llltUltlVely that epidermis may secrete other gene products 
that may regulate extracellular or systemic responses . 
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WHAT IS SECRETION? 
To estimate the extent to which epidermis may function as a secre-
tory tissue, it is important to define secretion. Cytokines or adhesion 
molecules that are externalized but bind immediately to receptors 
and act on the cell that produce them are autocri/"Ie, or juxtacrine if 
acting on cells with which they are in contact. In the case of trans-
forming growth factor alpha (TGF-a), affinities between external-
ized ligand and receptors for epidermal growth factor (EGF) are 
sufficiently high that the probability for escape of free TGF-a into 
the environment is diminishingly small [14] . Paracrine action in the 
skin is exemplified by the complementary exchange of factors in the 
epithelial-mesenchymal axis l15] that neither remain in their re-
spective tissue compartment nor arrive in the lymphatic or vascular 
circulations. Heparin-binding growth factors [16J are examples of 
cytokines that are released but are bound locally to tissue matrix. 
Gene products of keratinocytes that enter the circulation and induce 
specific biologic responses in target tissues act by endocrine mecha-
nisms. Glandular epithelia (sebaceous and sweat) of the skin are 
specialized for exocri ne functions of tissue homeostasis. Most reports 
of expression of gene products by keratinocytes describe autocrine, 
juxtacrine, or paracrine activities. But, if secretion is defined as 
molecular release and translocation, then paracrine, endocrine, and 
exocrine activities are most consistent with this definition. How-
ever, with regard to systemic responses or prospective therapies, 
endocrine delivery of gene products by keratinocytes is the most 
pertinent mechanism of secretion. 
EPIDERMIS AS AN ENDOCRINE TISSUE 
Because uninjured epidermis functions primarily as a self-regener-
ating protective barrier of the body with the external environment, 
its participation in regulation of systemic physiology is restricted to 
control of fluid loss and microbial infection. These homeostatic 
functions do not require induction of local or systemic responses, 
and at present, uninjured epidermis is not known to deliver physio-
logically relevant concentrations of any peptide, lipid, or carbohy-
drate mediators into the circulation. In sharp contrast, after injury, 
epidermal cytokines are known to stimulate local and systemic re-
sponses, for recruitment of immune effector cells from the circula-
tion [2] , and for proliferation and differentiated function of paren-
chymal cells (e.g., fibroblasts, vascular endothelium, nerve). Local 
responses of keratinocytes to injury stimulate acute or chronic in-
flammation, which leads to either resolution or persistence of the 
local tissue symptoms. However, if the disease involves extensive 
proportions of the body surface (e.g., major burns, auto-immune 
conditions, congenital anomalies, anaphylaxis), it has been postu-
lated that the absolute levels of keratinocyte gene products (i.e., 
IL-1 and other inflammatory mediators) released into the circula-
tion may contribute directly to acute phase response and hyperme-
tabolism [17] . It must also be appreciated that high circulating levels 
of keratinocyte gene products in disease that is extensive and acute 
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may result as. much o~ mo.re from keratinocyte lysis as from actual 
secretion by mtact epithelIUm. 
Notwithstanding the native biology and pathology of epidermis, 
emerging technologies have opened new possibilities for considera-
tion of epidermis as an endocrine tissue. Advances in culture and 
transplantation of epidermal keratinocytes [18,19] have demon-
strated regeneration of epidermis that restores homeostatic barrier 
to fluid loss and microbial infection. Although the kinetics of 
wound healing with cultured epithelium are slower than with na-
tive skin grafts, comparable processes of inflammation, hypertrophy 
of parenchymal cells, ~nd tiss~e remodelling o~cur in skin regenera-
tion with cultured skm substitutes. The persistence of autologous 
cultured keratinocytes after healing of wounds has been substan-
tiated indirectly by indefinite closure of large, full-thickness burns 
with cultured epithelium. This hypothesis is also supported by the 
persistence ~f gra~ts ~f cultured human. keratin~cytes 011 athymic 
mice for their entire bfespan [20]. Graftmg studies have now been 
extended to transplantation of cultured skin substitutes containing 
allogeneic cultured keratinocytes [21]. In contrast to autologous 
keratinocytes, DNA restriction endonuclease analysis [22] after 
treatment of skin ulcers or partial-thickness burns suggests 
strongly that allogeneic keratinocytes engraft, form epidermis, 
and then are replaced by ingrowth of autologous keratinocytes from 
the host. However, replacement of allogeneic keratinocytes does 
not stimulate typical T-cell- mediated graft rejection. This may be 
accounted for, in part, because allogeneic Langerhans cells, rich in 
HLA-DR antigens, do not survive in keratinocyte cultures [23]. 
Rather, it is postulated that allogeneic keratinocytes facilitate 
wound healing by delivery of cytokines, which promote the growth 
of fibrovascular tissue, and by the regeneration of basement mem-
brane on which autologous keratinocytes can migrate [24]. If 
these mechanisms are found to be consistent for treatment of acute 
and chronic wounds, then cultured allogeneic keratinocytes may 
serve as vehicles for temporary delivery of therapeutic gene prod-
ucts. 
Recognition of the indefinite or temporary persistence of cul-
tured autologous or allogeneic keratinocytes, respectively, has 
sparked the attention of molecular biologists. An exciting demon-
stration for feasibility of gene therapy has been made by the graft-
ing to athymic mice of human keratinocytes after transfection in 
culture with the gene for human growth hormone [25]. Products of 
the transfected gene have been detected in the transplanted epithe-
lium, but not in the blood of the host. Similar studies have been 
performed recently by transfection of cultured human keratinocytes 
with the human fJ-chorionic gonadotrophin (fJ-hCG) gene [26]. 
Accumulation of the transfected gene product in culture medium 
increased 15 times over a 21-d period. These important studies 
indicate that gene therapy by transplantation of transfected kerati-
nocytes is feasible. Epidermis regenerated from transfected kerati-
nocytes could function as endocrine tissue for prospective treatment 
of certain heritable disorders including, but not limited to, hemo-
philia, diabetes, hypothyroidism, dwarfism, cystic fibrosis, and in-
fertility. 
GENETICALLY ENGINEERED EPIDERMIS 
TO TREAT DISEASE 
Somatic gene therapy is an ultimate goal of modern medicine be-
cause it promises to correct the biologic basis of disease, rather than 
to treat its symptoms. However, some clinicians may consider that 
many congenital diseases are treated safely and effectively by phar-
maceutical therapy with recombinant pep tides. Hemophilia can be 
treated with factor VIII, diabetes with insulin, and dwarfism with 
growth hormone. Although most of these disorders may be man-
aged effectively by periodic medication, the need for regulation of 
physiologic blood levels of the respective compounds has resulted in 
the development of complex infusion devices, which impose 
chronic inconvenience and expense to the patient. Biologic regula-
tion of drug delivery is an essential advantage, and perhaps the 
greatest challenge of gene therapy. 
If native structure, function, delivery, and regulation of en do-
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crine gene products are assumed to be acceptable models for the 
delivery of keratinocyte gene products fr0111 transfected epidermis, 
then a multiplicity of requirements must be satisfied [27,28]. First, 
the biologic stability of the transfected genes must be established 
within the transfected cells, and the stability of transfected cells 
within transplanted tissue. Second, quantitative and kinetic expres-
sion of the gene product must be sufficient to meet the metabolic 
requirements of the host for resolution of the disease symptoms. 
Depending on the type of gene vector and its regulation, the prolif-
erative or differentiated state of the transfected cells may influence 
dramatically expression of the transfected gene. Third, structural 
homology of the transfected gene product with its native counter-
part must be sufficient to provide comparable biologic activity. 
Fourth, delivery of the peptide to the blood should not result in 
excessive local accumulations between the secretory epithelium and 
vascular plexus. And very importantly, negative feedback mecha-
nisms should exist to downregulate delivery of the drug. Native 
antagonists, or neuro-endocrine mechanisms for downregulation, 
may not function in transfected epidermis. 
Katz and Taichman (12) report in this issue systematic studies to 
address some of these fundamental questions. Recognizing that 
dermis acts as a filter between epidermis and vascular circulation, an 
it, vitro model was constructed for direct detection and measurement 
of secretion by cultured human epidermal keratinocytes . Total pro-
tein secreted by keratinocytes was shown to be 10-20 J.l.g/106 cells 
within 24 h. Accumulation of 35S-labeled protein was time depen-
dent, and about 70 molecular species were resolved by two-dimen-
sional electrophoresis. Protein accumulation in culture medium was 
blocked by exposure to Brefeldin A, an inhibitor of secretion. Using 
the same model, Barra and colleagues [11] demonstrated convinc-
ingly that keratinocyte size correlates inversely with secretion of 
35S-Apo E, but was not related to labeling index with bromo-deoxy-
uridine (BrdU). These findings indicate that expression of certain 
keratinocyte gene products is independent of cell replication, but 
localized to the smaller, basal-like cells. This implies that the re-
duced metabolic rate of uninjured epidermis may not reduce consti-
tutive secretion by keratinocytes. From a modeling perspective, this 
approach is convincing, but does not allow estimation of the frac-
tion of secreted ApoE that may reach the vascular circulation in vitJO. 
And, although Apo E from normal human keratinocytes has been 
detected in blood of athymic mice grafted with cultured human 
epithelium [13], detection of gene products of transfected keratino-
cytes in the blood has not been shown. Assuming that delivery to the 
blood of gene products from transfected keratinocytes can be ac-
complished, plasma levels of drug would be directly proportional to 
the area of grafted epithelium required for therapeutic efficacy. For 
clinical practicality, the expression of transfected genes would need 
to be sufficiently high to minimize the area grafted with genetically 
modified epithelium. 
Potentials for permanent correction of congenital disorders have 
promoted more extensive study of gene therapy in other medical 
disciplines than in dermatology. Prospective applications of somatic 
gene therapy include transfection of bone marrow or liver to maxi-
mize systemic output [29,30). Congenital disorders of specific 
organs (e.g., brain, lung, heart, kidney, muscle) may best be served 
by targeting transfected genes to respective organs (31). Although 
most models of somatic gene therapy use retroviral vectors, they 
could be eliminated by homologous recombination of a functional 
gene into a defective gene [28]. Many impressive examples of phe-
notypic modification have resulted from studies with transgenic 
mice, but most of these genetic modifications are not heritable, 
confer sterility, or are lethal [32]. If genetic modifications were 
stable and heritable, then far-reaching ethical questions would be 
raised regarding population eugenics. Among these considerations, 
epidermis is highly probable to be utilized as a delivery device for 
somatic gene therapy. Because the medical prospects for gene ther-
apy are broad, convergent knowledge from parallel efforts in unre-
lated disciplines of medicine may be expected to contribute to ad-
vances toward the understanding, regulation, and engineering of 
epidermis as a secretory tissue. 
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